{"id": "GZWSZq4AAAAJ", "citedby": 12807, "citedby5y": 4758, "hindex": 61, "hindex5y": 38, "i10index": 127, "i10index5y": 80, "coauthors": [{"id": "RrY0SpUAAAAJ", "name": "Arthur M. Krieg", "affiliation": "Checkmate Pharma"}, {"id": "q6uROkUAAAAJ", "name": "Bernd Jahrsdoerfer", "affiliation": "Professor f\u00fcr Klinische Pharmakologie"}, {"id": "yI9ON-UAAAAJ", "name": "Aliasger Salem", "affiliation": "Bighley Chair and Professor of Pharmaceutical Sciences, University of Iowa College of Pharmacy"}], "name": "George J Weiner", "affiliation": "Director, Holden Comprehensive Cancer Center, Professor of Internal Medicine, University of Iowa", "interests": ["cancer", "immunology", "lymphoma"], "cites_per_year": {"1995": 58, "1996": 39, "1997": 60, "1998": 111, "1999": 145, "2000": 231, "2001": 296, "2002": 332, "2003": 422, "2004": 465, "2005": 438, "2006": 435, "2007": 429, "2008": 432, "2009": 565, "2010": 578, "2011": 620, "2012": 724, "2013": 742, "2014": 752, "2015": 896, "2016": 863, "2017": 907, "2018": 897, "2019": 858, "2020": 314}, "publications": [{"bib": {"title": "CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells", "year": "1999"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:u5HHmVD_uO8C", "citedby": "779"}, {"bib": {"title": "Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization", "year": "1997"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:u-x6o8ySG0sC", "citedby": "636"}, {"bib": {"title": "Rituximab: mechanism of action", "year": "2010"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:9yKSN-GCB0IC", "citedby": "571"}, {"bib": {"title": "Cancer immunotherapy comes of age", "year": "2011"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:IjCSPb-OGe4C", "citedby": "456"}, {"bib": {"title": "Building better monoclonal antibody-based therapeutics", "year": "2015"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:O3NaXMp0MMsC", "citedby": "393"}, {"bib": {"title": "Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines", "year": "2001"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:2osOgNQ5qMEC", "citedby": "362"}, {"bib": {"title": "Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia: 10,000/microL versus 20,000/microL.", "year": "1997"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:qjMakFHDy7sC", "citedby": "327"}, {"bib": {"title": "Cancer and inflammation: promise for biological therapy", "year": "2010"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:zYLM7Y9cAGgC", "citedby": "324"}, {"bib": {"title": "Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs", "year": "2001"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:d1gkVwhDpl0C", "citedby": "301"}, {"bib": {"title": "Methods for enhancing antibody-induced cell lysis and treating cancer", "year": "2009"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:_Qo2XoVZTnwC", "citedby": "290"}, {"bib": {"title": "Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma", "year": "1997"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:UeHWp8X0CEIC", "citedby": "259"}, {"bib": {"title": "Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab", "year": "2006"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:Y0pCki6q_DkC", "citedby": "223"}, {"bib": {"title": "Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma", "year": "2010"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:ufrVoPGSRksC", "citedby": "210"}, {"bib": {"title": "NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement", "year": "2008"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:LkGwnXOMwfcC", "citedby": "194"}, {"bib": {"title": "Uses of granulocyte-macrophage colony-stimulating factor in vaccine development", "year": "2000"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:YsMSGLbcyi4C", "citedby": "192"}, {"bib": {"title": "Bispecific antibodies in cancer therapy", "year": "1999"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:Tyk-4Ss8FVUC", "citedby": "191"}, {"bib": {"title": "Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge", "year": "2015"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:isC4tDSrTZIC", "citedby": "190"}, {"bib": {"title": "CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens", "year": "2001"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:WF5omc3nYNoC", "citedby": "174"}, {"bib": {"title": "Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia", "year": "2013"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:aqlVkmm33-oC", "citedby": "167"}, {"bib": {"title": "CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells", "year": "2005"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:8k81kl-MbHgC", "citedby": "162"}, {"bib": {"title": "Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor", "year": "1998"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:W7OEmFMy1HYC", "citedby": "161"}, {"bib": {"title": "Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence", "year": "1994"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:_FxGoFyzp5QC", "citedby": "161"}, {"bib": {"title": "B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides", "year": "2005"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:UebtZRa9Y70C", "citedby": "157"}, {"bib": {"title": "A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma", "year": "2008"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:hqOjcs7Dif8C", "citedby": "154"}, {"bib": {"title": "Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin\u2019s lymphoma with rituximab and interferon-\u03b1-2a", "year": "2000"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:eQOLeE2rZwMC", "citedby": "149"}, {"bib": {"title": "Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma", "year": "2006"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:Se3iqnhoufwC", "citedby": "146"}, {"bib": {"title": "The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides", "year": "2000"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:roLk4NBRz8UC", "citedby": "142"}, {"bib": {"title": "Active choice but not too active: public perspectives on biobank consent models", "year": "2011"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:YOwf2qJgpHMC", "citedby": "131"}, {"bib": {"title": "Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody \u2026", "year": "2009"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:Zph67rFs4hoC", "citedby": "128"}, {"bib": {"title": "Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia", "year": "2011"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:Wp0gIr-vW9MC", "citedby": "126"}, {"bib": {"title": "Methods of treating cancer using immunostimulatory oligonucleotides", "year": "2011"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:mNrWkgRL2YcC", "citedby": "125"}, {"bib": {"title": "Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion", "year": "2010"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:4TOpqqG69KYC", "citedby": "124"}, {"bib": {"title": "CpG oligodeoxynucleotides as immunotherapy in cancer", "year": "2008"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:4DMP91E08xMC", "citedby": "121"}, {"bib": {"title": "B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation", "year": "2006"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:MXK_kJrjxJIC", "citedby": "120"}, {"bib": {"title": "Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma", "year": "2014"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:hMod-77fHWUC", "citedby": "118"}, {"bib": {"title": "Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non\u2013Hodgkin's lymphoma", "year": "2007"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:5nxA0vEk-isC", "citedby": "118"}, {"bib": {"title": "Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma", "year": "2014"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:RHpTSmoSYBkC", "citedby": "115"}, {"bib": {"title": "HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor", "year": "1996"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:0EnyYjriUFMC", "citedby": "111"}, {"bib": {"title": "Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells", "year": "2005"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:ULOm3_A8WrAC", "citedby": "108"}, {"bib": {"title": "Early event status informs subsequent outcome in newly diagnosed follicular lymphoma", "year": "2016"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:q3CdL3IzO_QC", "citedby": "106"}, {"bib": {"title": "Monoclonal antibody mechanisms of action in cancer", "year": "2007"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:_kc_bZDykSQC", "citedby": "106"}, {"bib": {"title": "Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195", "year": "2003"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:KlAtU1dfN6UC", "citedby": "105"}, {"bib": {"title": "CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations", "year": "2003"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:kNdYIx-mwKoC", "citedby": "100"}, {"bib": {"title": "APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells", "year": "2000"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:3fE2CSJIrl8C", "citedby": "97"}, {"bib": {"title": "Analysis of heritability and shared heritability based on genome-wide association studies for 13 cancer types", "year": "2015"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:D_sINldO8mEC", "citedby": "96"}, {"bib": {"title": "Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism", "year": "2011"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:qUcmZB5y_30C", "citedby": "95"}, {"bib": {"title": "Complement and cellular cytotoxicity in antibody therapy of cancer", "year": "2008"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:9ZlFYXVOiuMC", "citedby": "93"}, {"bib": {"title": "The role of T cell activation in anti-CD3 x antitumor bispecific antibody therapy.", "year": "1994"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:qxL8FJ1GzNcC", "citedby": "88"}, {"bib": {"title": "Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles", "year": "2007"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:mVmsd5A6BfQC", "citedby": "83"}, {"bib": {"title": "Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines", "year": "2002"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:dhFuZR0502QC", "citedby": "83"}, {"bib": {"title": "Bispecific antibodies", "year": "2001"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:hC7cP41nSMkC", "citedby": "82"}, {"bib": {"title": "Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region", "year": "2014"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:HoB7MX3m0LUC", "citedby": "81"}, {"bib": {"title": "Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia", "year": "2012"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:HDshCWvjkbEC", "citedby": "81"}, {"bib": {"title": "A comparative study of the antigen\u2010specific immune response induced by co\u2010delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles", "year": "2007"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:L8Ckcad2t8MC", "citedby": "76"}, {"bib": {"title": "Positron emission tomographic measurement of bone marrow blood flow to the pelvis and lumbar vertebrae in young normal adults [published erratum appears in Blood 1994 Nov 15 \u2026", "year": "1994"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:7PzlFSSx8tAC", "citedby": "76"}, {"bib": {"title": "Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.", "year": "1991"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:M3ejUd6NZC8C", "citedby": "76"}, {"bib": {"title": "AACR cancer progress report 2013", "year": "2013"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:ns9cj8rnVeAC", "citedby": "70"}, {"bib": {"title": "Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia", "year": "2016"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:t7zJ5fGR-2UC", "citedby": "68"}, {"bib": {"title": "Humanization and characterization of the anti\u2010HLA\u2010DR antibody 1D10", "year": "2001"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:QIV2ME_5wuYC", "citedby": "68"}, {"bib": {"title": "Complement in monoclonal antibody therapy of cancer", "year": "2014"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:xtRiw3GOFMkC", "citedby": "62"}, {"bib": {"title": "Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines", "year": "2005"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:hFOr9nPyWt4C", "citedby": "62"}, {"bib": {"title": "CpG DNA and cancer immunotherapy: orchestrating the antitumor immune response", "year": "2003"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:IWHjjKOFINEC", "citedby": "58"}, {"bib": {"title": "Bispecific antibody effective to treat B-cell lymphoma and cell line", "year": "2000"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:mB3voiENLucC", "citedby": "58"}, {"bib": {"title": "AACR cancer progress report 2014", "year": "2014"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:4OULZ7Gr8RgC", "citedby": "54"}, {"bib": {"title": "GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present", "year": "2013"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:J_g5lzvAfSwC", "citedby": "53"}, {"bib": {"title": "Combination immunotherapy of low grade or follicular non-Hodgkin's lymphoma with rituximab and alpha interferon: interim analysis", "year": "1998"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:ZeXyd9-uunAC", "citedby": "53"}, {"bib": {"title": "CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapy.", "year": "2003"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:TQgYirikUcIC", "citedby": "52"}, {"bib": {"title": "Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the transferrin receptor", "year": "1995"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:R3hNpaxXUhUC", "citedby": "52"}, {"bib": {"title": "CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma", "year": "2000"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:e5wmG9Sq2KIC", "citedby": "51"}, {"bib": {"title": "Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen", "year": "2003"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:-f6ydRqryjwC", "citedby": "49"}, {"bib": {"title": "A genome-wide association study of marginal zone lymphoma shows association to the HLA region", "year": "2015"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:f2IySw72cVMC", "citedby": "45"}, {"bib": {"title": "Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas", "year": "2011"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:r0BpntZqJG4C", "citedby": "44"}, {"bib": {"title": "Biodegradable microparticles loaded with doxorubicin and CpG ODN for in situ immunization against cancer", "year": "2015"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:abG-DnoFyZgC", "citedby": "43"}, {"bib": {"title": "CpG oligodeoxynucleotide-based therapy of lymphoid malignancies", "year": "2009"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:JV2RwH3_ST0C", "citedby": "39"}, {"bib": {"title": "Monoclonal antibody therapy of B cell lymphoma", "year": "2004"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:iH-uZ7U-co4C", "citedby": "37"}, {"bib": {"title": "Germline variation in complement genes and event\u2010free survival in follicular and diffuse large B\u2010cell lymphoma", "year": "2012"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:rO6llkc54NcC", "citedby": "35"}, {"bib": {"title": "The pattern of clinical breast cancer metastasis correlates with a single nucleotide polymorphism in the C1qA component of complement", "year": "2006"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:blknAaTinKkC", "citedby": "35"}, {"bib": {"title": "Diagnosis-to-treatment interval is an important clinical factor in newly diagnosed diffuse large B-cell lymphoma and has implication for bias in clinical trials", "year": "2018"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:OTTXONDVkokC", "citedby": "34"}, {"bib": {"title": "Chemoimmunotherapy for relapsed/refractory and progressive 17p13\u2010deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low\u2010dose rituximab is \u2026", "year": "2014"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:lSLTfruPkqcC", "citedby": "34"}, {"bib": {"title": "Bispecific monoclonal antibody therapy of B-cell malignancy", "year": "1995"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:4JMBOYKVnBMC", "citedby": "34"}, {"bib": {"title": "Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer", "year": "2003"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:maZDTaKrznsC", "citedby": "33"}, {"bib": {"title": "CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice", "year": "2006"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:bEWYMUwI8FkC", "citedby": "32"}, {"bib": {"title": "Good prognosis cytogenetics in B-cell chronic lymphocytic leukemia is associated in vitro with low susceptibility to apoptosis and enhanced immunogenicity", "year": "2005"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:NMxIlDl6LWMC", "citedby": "32"}, {"bib": {"title": "Mitochondria control of cell death induced by anti-HLA-DR antibodies", "year": "2003"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:k_IJM867U9cC", "citedby": "32"}, {"bib": {"title": "Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma", "year": "2011"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:RGFaLdJalmkC", "citedby": "31"}, {"bib": {"title": "CpG DNA in cancer immunotherapy", "year": "2000"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:TFP_iSt0sucC", "citedby": "31"}, {"bib": {"title": "Anti\u2010CD3\u2010based bispecific antibody designed for therapy of human B\u2010cell malignancy can induce T\u2010cell activation by antigen\u2010dependent and antigen\u2010independent mechanisms", "year": "1998"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:M3NEmzRMIkIC", "citedby": "30"}, {"bib": {"title": "A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and 90yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B\u2010cell non\u2010Hodgkin \u2026", "year": "2013"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:M05iB0D1s5AC", "citedby": "29"}, {"bib": {"title": "Manipulation of cellular redox parameters for improving therapeutic responses in B\u2010cell lymphoma and multiple myeloma", "year": "2012"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:2P1L_qKh6hAC", "citedby": "29"}, {"bib": {"title": "A phase II study of Remitogen (Hu1D10), a humanized monoclonal antibody in patients with relapsed or refractory follicular, small lymphocytic, or marginal zone/MALT B-cell lymphoma", "year": "2001"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:j3f4tGmQtD8C", "citedby": "29"}, {"bib": {"title": "Anti-CD20 Monoclonal Antibody (mAb) with Enhanced Affinity for CD16 Activates NK Cells at Lower Concentrations and More Effectively Than Rituximab\u00ae.", "year": "2005"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:YFjsv_pBGBYC", "citedby": "26"}, {"bib": {"title": "Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma", "year": "2002"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:GnPB-g6toBAC", "citedby": "26"}, {"bib": {"title": "CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis", "year": "2013"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:a0OBvERweLwC", "citedby": "25"}, {"bib": {"title": "Anti-idiotypic antibodies recognizing stable epitopes limit the emergence of idiotype variants in a murine B cell lymphoma.", "year": "1990"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:BqipwSGYUEgC", "citedby": "25"}, {"bib": {"title": "Production and characterization of a bispecific IgG capable of inducing T-cell-mediated lysis of malignant B cells", "year": "1993"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:NaGl4SEjCO4C", "citedby": "23"}, {"bib": {"title": "CpG oligonucleotides as immunotherapeutic adjuvants: innovative applications and delivery strategies.", "year": "2009"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:35N4QoGY0k4C", "citedby": "22"}, {"bib": {"title": "Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance Fc receptor-mediated immunotherapies", "year": "2003"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:ZHo1McVdvXMC", "citedby": "22"}, {"bib": {"title": "Monoclonal antibodies in the treatment of human B-cell malignancies", "year": "1998"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:RYcK_YlVTxYC", "citedby": "21"}, {"bib": {"title": "Bispecific IgG and IL-2 therapy of a syngeneic B-cell lymphoma in immunocompetent mice.", "year": "1992"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:vV6vV6tmYwMC", "citedby": "21"}, {"bib": {"title": "Cohort profile: the lymphoma specialized program of research excellence (SPORE) molecular epidemiology resource (MER) cohort study", "year": "2017"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:8d8msizDQcsC", "citedby": "20"}, {"bib": {"title": "CpG oligodeoxynucleotides enhance Fc\u03b3RI-mediated cross presentation by dendritic cells", "year": "2004"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:3s1wT3WcHBgC", "citedby": "20"}, {"bib": {"title": "Picking the optimal target for antibody-drug conjugates", "year": "2013"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:yD5IFk8b50cC", "citedby": "19"}, {"bib": {"title": "Idiotype variants emerging after anti-idiotype monoclonal antibody therapy of a murine B cell lymphoma.", "year": "1989"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:g5m5HwL7SMYC", "citedby": "19"}, {"bib": {"title": "Elevated soluble IL\u20102 R \u03b1, IL\u20108, and MIP\u20101\u03b2 levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma", "year": "2014"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:tOudhMTPpwUC", "citedby": "18"}, {"bib": {"title": "Antibody therapy of lymphoma", "year": "2004"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:70eg2SAEIzsC", "citedby": "18"}, {"bib": {"title": "Immunostimulatory DNA sequences and cancer therapy", "year": "2000"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:pqnbT2bcN3wC", "citedby": "17"}, {"bib": {"title": "Immunoscintigraphy with111 In-satumomab pendetide in patients with colorectal adenocarcinoma: Performance and impact on clinical management", "year": "1994"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:fPk4N6BV_jEC", "citedby": "17"}, {"bib": {"title": "Minimally differentiated acute leukemia", "year": "1993"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:ldfaerwXgEUC", "citedby": "17"}, {"bib": {"title": "University of Iowa/Mayo Clinic Lymphoma SPORE", "year": "2004"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:SP6oXDckpogC", "citedby": "16"}, {"bib": {"title": "Genome-wide association study of event-free survival in diffuse large B-cell lymphoma treated with immunochemotherapy", "year": "2015"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:nrtMV_XWKgEC", "citedby": "15"}, {"bib": {"title": "Epidemiology and surveillance of amyotrophic lateral sclerosis in two large metropolitan areas in California", "year": "2015"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:WZBGuue-350C", "citedby": "15"}, {"bib": {"title": "Process for applying a polyurethane dispersion based foam to an article", "year": "2004"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:HeT0ZceujKMC", "citedby": "15"}, {"bib": {"title": "The safety and pharmacokinetics in adult subjects of an intravenously administered 99mTc-labeled 17 amino acid peptide (CYT-379)", "year": "1994"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:SeFeTyx0c_EC", "citedby": "15"}, {"bib": {"title": "Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose beta-glucan is well tolerated \u2026", "year": "2015"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:tS2w5q8j5-wC", "citedby": "14"}, {"bib": {"title": "Widespread use of complementary and alternative medicine among non-Hodgkin lymphoma survivors", "year": "2015"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:uWQEDVKXjbEC", "citedby": "14"}, {"bib": {"title": "RANDOMIZED EVALUATION OF THE OPTIMAL PLATELET COUNT FOR PROPHYLACTIC PLATELET TRANSFUSIONS IN PATIENTS UNDERGOING INDUCTION THERAPY FOR ACUTE-LEUKEMIA", "year": "1993"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:pyW8ca7W8N0C", "citedby": "14"}, {"bib": {"title": "Molecular characterization of anti-idiotype antibody-resistant variants of a murine B cell lymphoma.", "year": "1990"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:zA6iFVUQeVQC", "citedby": "14"}, {"bib": {"title": "Prostate cell surface antigen-specific antibodies", "year": "2003"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:D03iK_w7-QYC", "citedby": "13"}, {"bib": {"title": "Intestinal helminths regulate lethal acute graft-versus-host disease and preserve the graft-versus-tumor effect in mice", "year": "2015"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:V3AGJWp-ZtQC", "citedby": "12"}, {"bib": {"title": "B-CLL cells acquire APC-and CTL-like phenotypic characteristics after stimulation with CpG ODN and IL-21", "year": "2014"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:OU6Ihb5iCvQC", "citedby": "12"}, {"bib": {"title": "Three steps to breaking immune tolerance to lymphoma: a microparticle approach", "year": "2015"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:BrmTIyaxlBUC", "citedby": "11"}, {"bib": {"title": "The effects of CpG ODN on CLL proliferation, apoptosis or phenotype could have an impact on its clinical utility", "year": "2007"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:dfsIfKJdRG4C", "citedby": "11"}, {"bib": {"title": "Oral Tipifarnib (R115777) Has Single Agent Anti-Tumor Activity in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma (NHL): Results of a Phase II Trial in the University of \u2026", "year": "2006"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:u_35RYKgDlwC", "citedby": "11"}, {"bib": {"title": "Identification of candidate B-lymphoma genes by cross-species gene expression profiling", "year": "2013"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:K3LRdlH-MEoC", "citedby": "10"}, {"bib": {"title": "Prolonged clinical responses in patients with follicular lymphoma treated on a phase I trial of the anti-HLA-DR monoclonal antibody Remitogen (Hu1D10)", "year": "2001"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:cFHS6HbyZ2cC", "citedby": "10"}, {"bib": {"title": "Expression of both B7\u20101 and CD28 contributes to the IL\u20102 responsiveness of CTLL\u20102 cells", "year": "1996"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:b0M2c_1WBrUC", "citedby": "10"}, {"bib": {"title": "T cell activation and cytokine production in anti-CD3 bispecific antibody therapy", "year": "1995"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:EUQCXRtRnyEC", "citedby": "10"}, {"bib": {"title": "Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma", "year": "2017"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:LO7wyVUgiFcC", "citedby": "9"}, {"bib": {"title": "A Phase I Trial of CpG-7909, Rituximab Immunotherapy, and Y90 Zevalin Radioimmunotherapy for Patients (Pts) with Previously Treated CD20+ Non-Hodgkin Lymphoma (NHL).", "year": "2007"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:UxriW0iASnsC", "citedby": "9"}, {"bib": {"title": "Combination of CpG7909 and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL): A phase I, open label dose-escalation study of safety and \u2026", "year": "2004"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:bFI3QPDXJZMC", "citedby": "9"}, {"bib": {"title": "Bone marrow morphology during induction phase of therapy for acute myeloid leukemia (AML).", "year": "1995"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:NhqRSupF_l8C", "citedby": "8"}, {"bib": {"title": "Radiolabeled antibody imaging of patients with potentially resectable colorectal adenocarcinoma", "year": "1994"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:_xSYboBqXhAC", "citedby": "8"}, {"bib": {"title": "Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression", "year": "2018"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:HtEfBTGE9r8C", "citedby": "7"}, {"bib": {"title": "Essential components of cancer education", "year": "2015"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:JoZmwDi-zQgC", "citedby": "7"}, {"bib": {"title": "Short telomeres in B-CLL: the chicken or the egg?", "year": "2008"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:CHSYGLWDkRkC", "citedby": "7"}, {"bib": {"title": "Humanized antibodies against CD3", "year": "2008"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:2KloaMYe4IUC", "citedby": "7"}, {"bib": {"title": "Cancer Therapy and Prevention Based on Modulation of Complement activity", "year": "2007"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:738O_yMBCRsC", "citedby": "7"}, {"bib": {"title": "Hu1D10 induces apoptosis in vitro in human chronic lymphocytic leukemia cells (CLL) independent of compliment mediated lysis but requires Fc gamma receptor ligation.", "year": "1999"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:nb7KW1ujOQ8C", "citedby": "7"}, {"bib": {"title": "Complement-regulatory proteins CFHR1 and CFHR3 and patient response to anti-CD20 monoclonal antibody therapy", "year": "2017"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:XoXfffV-tXoC", "citedby": "6"}, {"bib": {"title": "Pentostatin, alemtuzumab, and low dose rituximab is effective therapy for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL)", "year": "2011"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:KxtntwgDAa4C", "citedby": "6"}, {"bib": {"title": "A phase II study of the farnesyltransferase inhibitor tipifarnib demonstrates anti-tumor activity in patients with relapsed and refractory lymphomas", "year": "2010"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:P5F9QuxV20EC", "citedby": "6"}, {"bib": {"title": "Hu1D10 induces parallel death and survival signals in chronic lymphocytic leukemia (CLL) cells: Justification for combination studies of Hu1D10 with PI3 kinase inhibitors.", "year": "2002"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:1sJd4Hv_s6UC", "citedby": "6"}, {"bib": {"title": "Time from diagnosis to initiation of treatment of DLBCL and implication for potential selection bias in clinical trials", "year": "2016"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:hCrLmN-GePgC", "citedby": "5"}, {"bib": {"title": "Methods of identifying metastatic potential in cancer", "year": "2006"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:q3oQSFYPqjQC", "citedby": "5"}, {"bib": {"title": "Phosphorothyoate oligodeoxynucleotides block nonspecific binding of Cy5 conjugates to monocytes", "year": "2005"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:LPZeul_q3PIC", "citedby": "5"}, {"bib": {"title": "Rituximab: complementary mechanisms of action", "year": "2003"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:dshw04ExmUIC", "citedby": "5"}, {"bib": {"title": "Prostate cell surface antigen-specific antibodies", "year": "2001"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:QYdC8u9Cj1oC", "citedby": "5"}, {"bib": {"title": "5E10: a prostate-specific surface-reactive monoclonal antibody", "year": "1998"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:p2g8aNsByqUC", "citedby": "5"}, {"bib": {"title": "Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19", "year": "2020"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:ZzlSgRqYykMC", "citedby": "4"}, {"bib": {"title": "GA101-Coated Target Cells Are More Effective Than Rituximab-Coated Target Cells at Activating NK Cells When Complement Is Present.", "year": "2009"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:vRqMK49ujn8C", "citedby": "4"}, {"bib": {"title": "275. Immunostimulatory Antigen Loaded Microparticles as Cancer Vaccines", "year": "2006"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:4fKUyHm3Qg0C", "citedby": "4"}, {"bib": {"title": "A Polymorphism in the C1qA Component of Complement Correlates with Prolonged Complete Remission Following Rituximab Therapy of Follicular Lymphoma.", "year": "2005"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:u9iWguZQMMsC", "citedby": "4"}, {"bib": {"title": "Serum alters the uptake and biologic activity of CpG oligodeoxynucleotides in B cell chronic lymphocytic leukemia", "year": "2005"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:Tiz5es2fbqcC", "citedby": "4"}, {"bib": {"title": "Humanized antibodies against CD3", "year": "2004"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:VL0QpB8kHFEC", "citedby": "4"}, {"bib": {"title": "CpG DNA as monotherapy for lymphoma: Linking innate and adaptive immunity.", "year": "2002"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:geHnlv5EZngC", "citedby": "4"}, {"bib": {"title": "Bispecific antibodies for retargeting anticancer cytotoxic lymphocytes", "year": "2001"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:mvPsJ3kp5DgC", "citedby": "4"}, {"bib": {"title": "Select unmethylated CpG oligodeoxynucleotides improve antibody dependent cellular cytotoxicity in vitro of both murine and human B cell lymphomas", "year": "1995"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:WbkHhVStYXYC", "citedby": "4"}, {"bib": {"title": "Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and PGG beta glucan is well tolerated and achieves high complete remission rates", "year": "2015"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:YohjEiUPhakC", "citedby": "3"}, {"bib": {"title": "Activation of NK cell responses and immunotherapy of cancer", "year": "2014"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:kRWSkSYxWN8C", "citedby": "3"}, {"bib": {"title": "Early Treatment of High Risk Chronic Lymphocytic Leukemia with Alemtuzumab, Rituximab, and PGG Beta Glucan: A Phase I Clinical Trial", "year": "2012"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:1qzjygNMrQYC", "citedby": "3"}, {"bib": {"title": "EBV (+) Diffuse Large B Cell Lymphoma Is Infrequent in Upper Central United States and Lacks Unique Clinical Characteristics or Adverse Prognosis Compared to EBV \u2026", "year": "2012"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:5Ul4iDaHHb8C", "citedby": "3"}, {"bib": {"title": "Vitamin D Deficiency Is Associated with Inferior Event-Free and Overall Survival in Diffuse Large B-Cell Lymphoma.", "year": "2009"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:eflP2zaiRacC", "citedby": "3"}, {"bib": {"title": "Measuring granulocyte and monocyte accumulation at malignant lymphoma sites", "year": "2009"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:08ZZubdj9fEC", "citedby": "3"}, {"bib": {"title": "The C3b component of complement inhibits NK cell activation induced by rituximab-coated target cells.", "year": "2006"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:l7t_Zn2s7bgC", "citedby": "3"}, {"bib": {"title": "Phase I study to assess safety and activity of oligodeoxynucleotide CpG 7909 (Promune (TM)) in patients with previously treated non-Hodgkin's lymphoma.", "year": "2001"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:VOx2b1Wkg3QC", "citedby": "3"}, {"bib": {"title": "Applications of immune stimulatory CpG DNA for antigen-specific and antigen-nonspecific cancer immunotherapy", "year": "1999"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:sSrBHYA8nusC", "citedby": "3"}, {"bib": {"title": "T-cell activation induced by anti-CD3\u00d7 anti-B-cell lymphoma monoclonal antibody is enhanced by pretreatment of lymphoma cells with soluble CD40 ligand", "year": "1997"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:J-pR_7NvFogC", "citedby": "3"}, {"bib": {"title": "The pharmacokinetics and diagnostic accuracy of low-dose indium 111-labeled B72. 3 (CYT-103) in patients with metastatic breast cancer", "year": "1993"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:B3FOqHPlNUQC", "citedby": "3"}, {"bib": {"title": "Antibody Opsonization of a TLR9 Agonist\u2013Containing Virus-like Particle Enhances In Situ Immunization", "year": "2020"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:Ehil0879vHcC", "citedby": "2"}, {"bib": {"title": "Diagnosis-to-treatment interval (DTI) remains associated with adverse clinical characteristics and outcome in newly diagnosed patients with diffuse large B-cell lymphoma \u2026", "year": "2017"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:a9-T7VOCCH8C", "citedby": "2"}, {"bib": {"title": "Vitamin D insufficiency is associated with an increased risk of early clinical failure in follicular lymphoma", "year": "2016"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:5qfkUJPXOUwC", "citedby": "2"}, {"bib": {"title": "Novel IL-2Ralpha (CD25)-Binding RNA Aptamer to Target T Regulatory Cells", "year": "2016"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:0N-VGjzr574C", "citedby": "2"}, {"bib": {"title": "Combination cancer immunotherapy using checkpoint blockade and intratumoral virus-like particles containing CpG ODN", "year": "2016"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:HbR8gkJAVGIC", "citedby": "2"}, {"bib": {"title": "Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/mayo \u2026", "year": "2015"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:9Nmd_mFXekcC", "citedby": "2"}, {"bib": {"title": "Assessing response to anti-CD20 therapy by genotyping C1q components", "year": "2010"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:t6usbXjVLHcC", "citedby": "2"}, {"bib": {"title": "Treatment of B cells with IL-21 and B cell activators induces Granzyme B production", "year": "2007"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:0KyAp5RtaNEC", "citedby": "2"}, {"bib": {"title": "Method to decrease nonspecific staining by Cy5", "year": "2006"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:9vf0nzSNQJEC", "citedby": "2"}, {"bib": {"title": "Immunostimulatory CpG oligodeoxynucleotide is effective as an adjuvant in inducing production of anti-idiotype antibody and is synergistic with GMCSF.", "year": "1996"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:eJXPG6dFmWUC", "citedby": "2"}, {"bib": {"title": "Immunostimulatory oligodeoxynucleotides containing CPG motifs enhance antibody dependent cytotoxicity in vitro and improve the efficacy of monoclonal antibody therapy in vivo.", "year": "1996"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:HE397vMXCloC", "citedby": "2"}, {"bib": {"title": "MEASUREMENT OF BONE-MARROW BLOOD-FLOW IN PATIENTS WITH ACUTE-LEUKEMIA AND OTHER BONE-MARROW DISORDERS USING POSITRON EMISSION TOMOGRAPHY", "year": "1993"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:fQNAKQ3IYiAC", "citedby": "2"}, {"bib": {"title": "Combining Doxorubicin-Loaded Pegylated Poly (Lactide-Co-Glycolide) Nanoparticles with Checkpoint Inhibition Safely Enhances Therapeutic Efficacy in a Melanoma Model", "year": "2019"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:P7Ujq4OLJYoC", "citedby": "1"}, {"bib": {"title": "An RNA Aptamer\u2013Based Biomarker Platform Demonstrates High Soluble CD25 Occupancy by IL2 in the Serum of Follicular Lymphoma Patients", "year": "2019"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:F9fV5C73w3QC", "citedby": "1"}, {"bib": {"title": "Combination Lymphoma Immunotherapy Using Checkpoint Blockade and Intratumoral Virus-like Particles Containing CpG TLR9 Agonist", "year": "2016"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:FPJr55Dyh1AC", "citedby": "1"}, {"bib": {"title": "VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human \u2026", "year": "2015"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:AvfA0Oy_GE0C", "citedby": "1"}, {"bib": {"title": "Identification of USP14 and UCHL5 As Druggable Oncotargets in Ibrutinib-Resistant Mantle Cell Lymphoma", "year": "2015"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:z_wVstp3MssC", "citedby": "1"}, {"bib": {"title": "Anti-Lymphoma Monoclonal Antibodies: Making Better Antibodies and Making Antibodies Better", "year": "2015"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:tKAzc9rXhukC", "citedby": "1"}, {"bib": {"title": "Three Steps to Breaking Immune Tolerance: A Microparticle Approach", "year": "2014"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:_B80troHkn4C", "citedby": "1"}, {"bib": {"title": "Rates and Outcomes of Follicular Lymphoma Transformation in the Rituximab Era: A Report From the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource", "year": "2012"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:j8SEvjWlNXcC", "citedby": "1"}, {"bib": {"title": "CD16 and NK cell activation: 840", "year": "2011"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:tzM49s52ZIMC", "citedby": "1"}, {"bib": {"title": "Making a better antibody: all is not lost", "year": "2010"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:wbdj-CoPYUoC", "citedby": "1"}, {"bib": {"title": "Germline Variation in Complement Genes and Event-Free Survival in Follicular Lymphoma.", "year": "2009"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:WA5NYHcadZ8C", "citedby": "1"}, {"bib": {"title": "Assessment of peripheral blood mononuclear cell (PBMC) trafficking in patients with non-Hodgkin's lymphoma (NHL) prior to and following therapy", "year": "2006"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:Mojj43d5GZwC", "citedby": "1"}, {"bib": {"title": "Imaging of Peripheral Blood Mononuclear Cells (PBMC) Trafficking in Patients with Non-Hodgkin\u2019s Lymphoma (NHL) Prior to and Following Therapy.", "year": "2005"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:bnK-pcrLprsC", "citedby": "1"}, {"bib": {"title": "In Vitro Activity of the Humanized Anti-HLA-DR Antibodies KRN848 and Apolizumab in Non-Hodgkins Lymphoma Cell Lines.", "year": "2005"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:5ugPr518TE4C", "citedby": "1"}, {"bib": {"title": "Brachytherapy Combined with CpG ODN Enhances Development of a Tumor Antigen-Specific CD8 Response.", "year": "2004"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:LI9QrySNdTsC", "citedby": "1"}, {"bib": {"title": "Persistent thrombocytopenia during remission in acute leukemia does not preclude long\u2010term disease\u2010free survival", "year": "2002"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:Z5m8FVwuT1cC", "citedby": "1"}, {"bib": {"title": "CpG oligodeoxynucleotides and monoclonal antibody therapy of lymphoma", "year": "2002"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:olpn-zPbct0C", "citedby": "1"}, {"bib": {"title": "The combination of oligodeoxynucleotides containing immunostimulatory CpG sequences and T-cell help enhances the ability of antigen pulsed-dendritic cells to activate class I \u2026", "year": "1999"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:AXPGKjj_ei8C", "citedby": "1"}, {"bib": {"title": "Humanized 1D10 monoclonal antibody for therapy of B-cell malignancies-Pre-clinical features", "year": "1998"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:XiVPGOgt02cC", "citedby": "1"}, {"bib": {"title": "Intraperitoneal CMP-001: A Novel Immunotherapy for Treating Peritoneal Carcinomatosis of Gastrointestinal and Pancreaticobiliary Cancer", "year": "2020"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:GFxP56DSvIMC", "citedby": "0"}, {"bib": {"title": "Abstract B24: The microbiome in lung cancer under immunotherapy: Significant compositional differences associated with treatment response and AEs", "year": "2020"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:Aul-kAQHnToC", "citedby": "0"}, {"bib": {"title": "The microbiome in lung cancer under immunotherapy: Significant compositional differences associated with treatment response and AEs.", "year": "2020"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:gVv57TyPmFsC", "citedby": "0"}, {"bib": {"title": "O85 Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab", "year": "2020"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:lvd772isFD0C", "citedby": "0"}, {"bib": {"title": "Rationally improving T cell-mediated cancer immunotherapies using Sleeping Beauty mutagenesis to identify novel therapeutic targets.", "year": "2020"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:5MTHONV0fEkC", "citedby": "0"}, {"bib": {"title": "Abstract A51: Rationally improving T cell-mediated cancer immunotherapies using Sleeping Beauty mutagenesis to identify novel therapeutic targets", "year": "2020"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:_OXeSy2IsFwC", "citedby": "0"}, {"bib": {"title": "Correction: Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19", "year": "2020"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:nVrZBo8bIpAC", "citedby": "0"}, {"bib": {"title": "Blockade of CD47-Sirp\u03b1 Interactions Improved Myeloid Effector Cell Mediated Lymphoma Cell Killing By the HLA-DR Antibody Apolizumab", "year": "2019"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:OP4eGU-M3BUC", "citedby": "0"}, {"bib": {"title": "OA03. 04 Analysis of Patient Microbiome and Its Correlation to Immunotherapy Response and Toxicity in Lung Cancer", "year": "2019"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:fbc8zXXH2BUC", "citedby": "0"}, {"bib": {"title": "P2. 04-18 Analysis of Patient Microbiome and Its Correlation to Immunotherapy Response and Toxicity in Lung Cancer", "year": "2019"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:u-coK7KVo8oC", "citedby": "0"}, {"bib": {"title": "CMP-001, a virus-like particle containing immunostimulatory CpG-A, for treatment of peritoneal carcinomatosis of gastrointestinal and pancreatic cancers", "year": "2019"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:r_AWSJRzSzQC", "citedby": "0"}, {"bib": {"title": "Methods for treating tumors in situ including intratumor injection of cytotoxic particles and immune checkpoint blockade therapy", "year": "2019"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:9c2xU6iGI7YC", "citedby": "0"}, {"bib": {"title": "NUCLEIC ACID APTAMERS", "year": "2019"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:yMeIxYmEMEAC", "citedby": "0"}, {"bib": {"title": "Helminth-Induced Production of TGF-\u03b2 and Suppression of Graft-versus-Host Disease Is Dependent on IL-4 Production by Host Cells", "year": "2018"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:4vMrXwiscB8C", "citedby": "0"}, {"bib": {"title": "Overcoming obesity-induced immunotherapeutic failure", "year": "2018"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:IUKN3-7HHlwC", "citedby": "0"}, {"bib": {"title": "Rationally improving T cell-mediated cancer immunotherapy using Sleeping Beauty mutagenesis to identify novel drug targets", "year": "2017"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:fFSKOagxvKUC", "citedby": "0"}, {"bib": {"title": "A novel assay using RNA aptamers to quantitate the fraction of IL2Ra (CD25) receptors occupied by IL2", "year": "2017"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:3htObqc8RwsC", "citedby": "0"}, {"bib": {"title": "Parasitic biological agents for treatment and prevention of graft versus host disease", "year": "2017"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:VLnqNzywnoUC", "citedby": "0"}, {"bib": {"title": "Targeting human T regulatory cells with novel Interleukin 2 alpha-IL2 complex-specific RNA aptamer", "year": "2017"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:FAceZFleit8C", "citedby": "0"}, {"bib": {"title": "Academic cancer center phase i program development", "year": "2017"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:9pM33mqn1YgC", "citedby": "0"}, {"bib": {"title": "Biodegradable particulate formulations", "year": "2017"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:SdhP9T11ey4C", "citedby": "0"}, {"bib": {"title": "No Association of EBV or Immunosuppression Status with Outcomes in US Patients with Diffuse Large B-Cell Lymphoma Treated in the Immunochemotherapy Era", "year": "2016"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:ClCfbGk0d_YC", "citedby": "0"}, {"bib": {"title": "Impact of therapeutic EGFR inhibition on immune checkpoint blockade in head and neck squamous cell carcinoma", "year": "2016"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:ruyezt5ZtCIC", "citedby": "0"}, {"bib": {"title": "Identification of novel cancer immunotherapy targets using Sleeping Beauty mutagenesis", "year": "2016"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:foquWX3nUaYC", "citedby": "0"}, {"bib": {"title": "Association of vitamin D insufficiency with inferior prognosis in follicular lymphoma.", "year": "2016"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:4fGpz3EwCPoC", "citedby": "0"}, {"bib": {"title": "Tu1874 The Recipient STAT6 Pathway Is Critical in Helminth-Induced Intestinal Immune Regulation and Mitigation of Graft-Versus-Host Disease (GVHD)", "year": "2016"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:e_rmSamDkqQC", "citedby": "0"}, {"bib": {"title": "191 Interleukin 4 Is Critical in Helminth-Induced Regulatory T-Cell Expansion and Suppression of Colitis in a Graft Versus Host Disease Model", "year": "2016"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:-FonjvnnhkoC", "citedby": "0"}, {"bib": {"title": "Generation of T regulatory-cell specific RNA aptamers", "year": "2015"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:oNZyr7d5Mn4C", "citedby": "0"}, {"bib": {"title": "EVENT-FREE SURVIVAL AT 12 MONTHS AND SUBSEQUENT OVERALL SURVIVAL IN PATIENTS WITH FOLLICULAR LYMPHOMA MANAGED IN THE RITUXIMAB ERA: 188", "year": "2015"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:LhH-TYMQEocC", "citedby": "0"}, {"bib": {"title": "A phase (Ph) 1/2 trial of rituximab (RX), imprime PGG (IP), and alemtuzumab (AL) in the early treatment of patients (Pts) with high risk chronic lymphocytic leukemia (CLL).", "year": "2015"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:kh2fBNsKQNwC", "citedby": "0"}, {"bib": {"title": "Clinical and Translational Results from a Phase II Trial of Imprime PGG, Alemtuzumab, and Rituximab in the Early Treatment of Patients with High Risk Chronic Lymphocytic Leukemia", "year": "2014"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:ILKRHgRFtOwC", "citedby": "0"}, {"bib": {"title": "Intestinal Helminth Colonization Regulates Lethal Graft Versus Host Disease and Preserves Graft Versus Tumor in Bone Marrow Transplanted Mice", "year": "2014"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:vbGhcppDl1QC", "citedby": "0"}, {"bib": {"title": "Intratumoral Inhibition of C5a Using Anti-C5a Monoclonal Antibody Inhibits Lymphoma Progression", "year": "2014"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:ye4kPcJQO24C", "citedby": "0"}, {"bib": {"title": "No Mechanism is an Island: Interactions Among Monoclonal Antibody Mechanisms of Action", "year": "2014"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:edDO8Oi4QzsC", "citedby": "0"}, {"bib": {"title": "Complement Factor H Related Protein 1 (CFHR1) Serum Level Correlates With Event-Free Survival In Follicular Lymphoma Patients Treated With Rituximab", "year": "2013"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:epqYDVWIO7EC", "citedby": "0"}, {"bib": {"title": "C5a Complement Depletion Suppresses In Vivo B Lymphoma Progression and Enhances Development Of Cellular Anti-Tumor Immune Response", "year": "2013"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:NJ774b8OgUMC", "citedby": "0"}, {"bib": {"title": "An Effective and Tolerable Chemoimmunotherapy Regimen For Relapsed/Refractory and Very-High Risk Chronic Lymphocytic Leukemia Combining Alemtuzumab With Pentostatin and Low \u2026", "year": "2013"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:kzcrU_BdoSEC", "citedby": "0"}, {"bib": {"title": "Antibody Fc: Chapter 14. No Mechanism is an Island: Interactions Among Monoclonal Antibody Mechanisms of Action", "year": "2013"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:Dip1O2bNi0gC", "citedby": "0"}, {"bib": {"title": "C5a Depletion As a Novel Strategy to Inhibit T Regulatory Cells and Enhance Antigen-Specific Immune Responses", "year": "2012"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:i2xiXl-TujoC", "citedby": "0"}, {"bib": {"title": "Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI", "year": "2012"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:kz9GbA2Ns4gC", "citedby": "0"}, {"bib": {"title": "Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era", "year": "2012"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:fEOibwPWpKIC", "citedby": "0"}, {"bib": {"title": "C5a complement enhances generation of APC-induced Foxp3+ T regulatory cells", "year": "2012"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:_Re3VWB3Y0AC", "citedby": "0"}, {"bib": {"title": "5.24 Pentostatin, Alemtuzumab, and Low-Dose Rituximab Is Effective Therapy for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "year": "2011"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:p__nRnzSRKYC", "citedby": "0"}, {"bib": {"title": "RITUXIMAB INFUSION INDUCES NK ACTIVATION IN LYMPHOMA PATIENTS WITH THE HIGH AFFINITY CD16 POLYMORPHISM", "year": "2011"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:URolC5Kub84C", "citedby": "0"}, {"bib": {"title": "Helminths Employ STAT6 Pathway to Induce TGF\u03b2 Positive T Lymphocytes to Regulate Colitis and Acute Graft Versus Host Disease", "year": "2011"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:W5xh706n7nkC", "citedby": "0"}, {"bib": {"title": "Complement promotes induction of Foxp3+ T regulatory cells by B lymphoma cells and professional antigen presenting cells", "year": "2011"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:OR75R8vi5nAC", "citedby": "0"}, {"bib": {"title": "Abstract LB-152: Complement promotes induction of Foxp3+ T regulatory cells by B lymphoma cells and professional antigen-presenting cells", "year": "2011"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:uc_IGeMz5qoC", "citedby": "0"}, {"bib": {"title": "Monoclonal Antibody Therapy of C M hi fA ti\u201d Cancer Mechanisms of Action", "year": "2011"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:Ug5p-4gJ2f0C", "citedby": "0"}, {"bib": {"title": "Production and characterization of a bispecific IgG capable of", "year": "2011"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:umqufdRvDiIC", "citedby": "0"}, {"bib": {"title": "Complement Enhances Foxp3+ T Regulatory Cell Induction by B Cell Lymphoma", "year": "2010"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:S16KYo8Pm5AC", "citedby": "0"}, {"bib": {"title": "CLL Cells From Subjects Treated with Rituximab and Alemtuzumab Can Lose Target Antigen and Develop Resistance to Mab-Mediated Complement Dependent Cytotoxicity", "year": "2010"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:tYavs44e6CUC", "citedby": "0"}, {"bib": {"title": "Induction of a CTL-Like Phenotype In B-CLL Cells Stimulated with Interleukin 21 and CpG Oligodeoxynucleotides", "year": "2010"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:7T2F9Uy0os0C", "citedby": "0"}, {"bib": {"title": "Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia.", "year": "2010"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:8xutWZnSdmoC", "citedby": "0"}, {"bib": {"title": "Plasmacytoid dendritic cells suppresses T cell expansion by secreting Granzyme B", "year": "2010"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:eMMeJKvmdy0C", "citedby": "0"}, {"bib": {"title": "Response: Complement in antibody therapy for lymphoma: both a help and a hindrance?", "year": "2009"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:dTyEYWd-f8wC", "citedby": "0"}, {"bib": {"title": "Rituximab Infusion Induces NK Activation in Subjects with the High Affinity CD16 Polymorphism.", "year": "2009"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:lmc2jWPfTJgC", "citedby": "0"}, {"bib": {"title": "Granzyme B Produced by Human Plasmacytoid Dendritic Cells Suppresses T Cell Expansion.", "year": "2009"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:b1wdh0AR-JQC", "citedby": "0"}, {"bib": {"title": "Stimulation of B-CLL Cells with Interleukin 21 and Toll Like Receptor Agonists Induces a CTL-Like Transcriptional Profile.", "year": "2009"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:zLWjf1WUPmwC", "citedby": "0"}, {"bib": {"title": "Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates.", "year": "2009"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:dBIO0h50nwkC", "citedby": "0"}, {"bib": {"title": "Cancer Stem Cell Activity in Mantle Cell Lymphoma Is Inhibited by TLR9 Activation", "year": "2008"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:VaXvl8Fpj5cC", "citedby": "0"}, {"bib": {"title": "Depletion of the C3 Component of Complement Enhances the Ability of Rituximab-Coated Target Cells to Activate Human NK Cells and Improves the Efficacy of Monoclonal Antibody \u2026", "year": "2008"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:XD-gHx7UXLsC", "citedby": "0"}, {"bib": {"title": "Human B lymphoma cell lines and primary B cells actively secrete Granzyme B in response to IL-2 family cytokines", "year": "2008"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:yB1At4FlUx8C", "citedby": "0"}, {"bib": {"title": "Humanized antibodies against cd3", "year": "2008"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:LjlpjdlvIbIC", "citedby": "0"}, {"bib": {"title": "The IPI Predicts Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: A Report of the University of Iowa/Mayo Clinic SPORE", "year": "2007"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:M7yex6snE4oC", "citedby": "0"}, {"bib": {"title": "A phase I trial of CpG-7909, rituximab immunotherapy, and Y90 Zevalin radioimmunotherapy for patients (Pts) with previously treated CD20+ non-Hodgkin lymphoma (NHL)", "year": "2007"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:L7CI7m0gUJcC", "citedby": "0"}, {"bib": {"title": "Human B Cell Lines and Primary B Cells Actively Secrete Granzyme B in Response to IL-2 Family Cytokines.", "year": "2007"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:_Ybze24A_UAC", "citedby": "0"}, {"bib": {"title": "Reply to \u2018Jahrsdorfer et al.\u2019", "year": "2007"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:xtoqd-5pKcoC", "citedby": "0"}, {"bib": {"title": "Interleukin 21-Based Therapy Can Induce Human B Cells To Produce Granzyme B and Express Other Features of Cytotoxic Lymphocytes.", "year": "2006"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:EkHepimYqZsC", "citedby": "0"}, {"bib": {"title": "IL-21 Plus CpG ODN Induces Granzyme B-Dependent Induction of Apoptosis in CD5-Positive B Cells Including B-CLL Cells.", "year": "2006"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:-_dYPAW6P2MC", "citedby": "0"}, {"bib": {"title": "Activated Human B Cells can Secrete Granzyme B and Gain Cytotoxic Potential in Response to Interleukin 21", "year": "2006"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:KUbvn5osdkgC", "citedby": "0"}, {"bib": {"title": "B-Chronic Lymphocytic Leukemia Cells and other B cells can produce Granzyme B and gain cytotoxic potential after Interleukin-21-based activation", "year": "2006"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:yFnVuubrUp4C", "citedby": "0"}, {"bib": {"title": "A Humanized HLA-DR Antibody (HU1D10, Apolizumab) in Combination with G-CSF (Filgrastim) for the Treatment of Non-Hodgkin\u2019s Lymphoma: A Pilot Study.", "year": "2005"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:86PQX7AUzd4C", "citedby": "0"}, {"bib": {"title": "A humanized HLA-DR antibody (HU1D1, Apolizumab) in combination with G-CSF (Filgrastim) for the treatment of non-Hodgkin's lymphoma: A pilot study.", "year": "2005"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:PVjk1bu6vJQC", "citedby": "0"}, {"bib": {"title": "IL-21 and CpG ODN Are Synergistic in Their Ability To Induce Apoptosis of Chronic Lymphocytic Leukemia (CLL) Cells and Benign B1 Cells.", "year": "2005"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:dQ2og3OwTAUC", "citedby": "0"}, {"bib": {"title": "10. T-cell Lymphoma/HIV-Lymphoma: 318 RITUXIMAB-INDUCED NK CELL ACTIVATION INCLUDES UPREGULATION OF CD54 (ICAM-1) AND IS DEPENDENT ON CD16 POLYMORPHISMS", "year": "2005"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:yqoGN6RLRZoC", "citedby": "0"}, {"bib": {"title": "Rituximab-induced NK cell activation includes upregulation of CD54 (ICAM-1) and is dependent on CD16 polymorphisms", "year": "2005"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:kuK5TVdYjLIC", "citedby": "0"}, {"bib": {"title": "Novel vaccine immunotherapy for B-cell malignancies using adenoviral delivery of \u03b1Galactosyltransferase gene", "year": "2005"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:k8Z6L05lTy4C", "citedby": "0"}, {"bib": {"title": "A comparative analysis of tumor immunity induced by peptide or cell-based vaccination", "year": "2005"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:BwyfMAYsbu0C", "citedby": "0"}, {"bib": {"title": "Cpg Oligodeoxynucleotide-Mediated Effects on B-Cell Chronic Lymphocytic Leukemia In Vitro Are Influenced by Cytogenetic Status and the Presence of Serum.", "year": "2004"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:hMsQuOkrut0C", "citedby": "0"}, {"bib": {"title": "Brachyimmunotherapy (Combination Brachytherapy and Immunotherapy) Enhances Development of a Tumor Antigen-Specific CD8 Response", "year": "2004"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:uLbwQdceFCQC", "citedby": "0"}, {"bib": {"title": "CPG Oligodeoxynucleotides Enhance Immunogenicity In Vitro in All Cytogenetic Subgroups of B-Cell Chronic Lymphocytic Leukemia (B-CLL), but Preferentially Augment Apoptosis in B \u2026", "year": "2004"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:eq2jaN3J8jMC", "citedby": "0"}, {"bib": {"title": "The production of bispecific antibodies The production of bispecific antibodies 1, 1998", "year": "2004"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:XvxMoLDsR5gC", "citedby": "0"}, {"bib": {"title": "Fc receptors Fc receptors, 2000", "year": "2004"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:4hFrxpcac9AC", "citedby": "0"}, {"bib": {"title": "Cancer biology: Lost in translation?", "year": "2004"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:PR6Y55bgFSsC", "citedby": "0"}, {"bib": {"title": "Humoral immunity induced by a cell-based tumor vaccine strategy", "year": "2004"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:hkOj_22Ku90C", "citedby": "0"}, {"bib": {"title": "Impact of cytogenetics on B-cell chronic lymphocytic leukemia survival and sensitivity to treatment with CpG oligonucleotides in-vitro.", "year": "2004"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:5awf1xo2G04C", "citedby": "0"}, {"bib": {"title": "Impact of CpG oligonucleotides on proliferation and survival of primary B-CLL cells.", "year": "2003"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:4MWp96NkSFoC", "citedby": "0"}, {"bib": {"title": "Monoclonal antibody bound to transformed B-cells enhances interferon gamma production and alters Fc receptor expression by autologous human NK and NKT cells.", "year": "2003"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:UHK10RUVsp4C", "citedby": "0"}, {"bib": {"title": "Current and Ongoing Clinical Development of Immunotherapy in B-Cell Malignancies Faculty Disclosure", "year": "2002"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:ZuybSZzF8UAC", "citedby": "0"}, {"bib": {"title": "Neutrophils and Fc gamma RI expression can contribute to antibody dependent cell-mediated cytotoxicity by anti-lymphoma monoclonal antibodies.", "year": "2001"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:tuHXwOkdijsC", "citedby": "0"}, {"bib": {"title": "APC Stimulated by CpG", "year": "2000"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:nZcligLrVowC", "citedby": "0"}, {"bib": {"title": "Commentary on \u201cThe History of the Development of Vaccines for the Treatment of Lymphoma\u201d", "year": "2000"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:evX43VCCuoAC", "citedby": "0"}, {"bib": {"title": "Immunotherapy of lymphoma using CgG oligodeoxynucleotides.", "year": "1999"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:N5tVd3kTz84C", "citedby": "0"}, {"bib": {"title": "CpG oligodeoxynucleotides enhance the ability of antigen-pulsed dendritic cells to activate MHC class I restricted T-cells.", "year": "1998"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:vDijr-p_gm4C", "citedby": "0"}, {"bib": {"title": "Bispecific antibody therapy", "year": "1998"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:TIZ-Mc8IlK0C", "citedby": "0"}, {"bib": {"title": "Anti-CD3 X anti-1D10 bispecific antibody retargets and enhances the cytotoxicity of cytokine induced killer cells.", "year": "1996"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:gsN89kCJA0AC", "citedby": "0"}, {"bib": {"title": "Evaluating B cell antibodies for their capacity to mediate ADCC.", "year": "1996"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:tkaPQYYpVKoC", "citedby": "0"}, {"bib": {"title": "EVALUATING B CELL PANEL ANTIBODIES IN ADCC WITH G-CSF NEUTROPHILS AS EFFECTOR CELLS: BC-1-11", "year": "1996"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:ipzZ9siozwsC", "citedby": "0"}, {"bib": {"title": "Production and initial evaluation of a humanized BsF (ab')(2) anti-CD3-based bispecific monoclonal antibody designed for therapy of human B-cell malignancies.", "year": "1995"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:35r97b3x0nAC", "citedby": "0"}, {"bib": {"title": "Expression of both B7-1 and CD28 Contributes to the IL-2 responsiveness of CTLL-2 cells", "year": "1995"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:ZfRJV9d4-WMC", "citedby": "0"}, {"bib": {"title": "Hla class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with G-CSF.", "year": "1995"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:JQOojiI6XY0C", "citedby": "0"}, {"bib": {"title": "Anti-idiotype antibody and CD40 ligand each induce expression of B7 molecules by malignant B-cells and enhance their ability to activate T-cells", "year": "1995"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:WqliGbK-hY8C", "citedby": "0"}, {"bib": {"title": "IRON DEPRIVATION TREATMENT OF MURINE LYMPHOMA IN-VITRO AND IN-VIVO-A COMPARISON OF PROTOCOLS USING EITHER ONE OR 2 IGG MONOCLONAL ANTITRANSFERRIN RECEPTOR ANTIBODIES WITH THE \u2026", "year": "1995"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:1yQoGdGgb4wC", "citedby": "0"}, {"bib": {"title": "ANTIIDIOTYPE ANTIBODY INDUCES ACTIVATION SIGNALS AND UP-REGULATES B7-2 EXPRESSION ON A MURINE B-CELL LYMPHOMA", "year": "1994"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:uWiczbcajpAC", "citedby": "0"}, {"bib": {"title": "ANTI-CD3-BASED BISPECIFIC ANTIBODY THERAPY INDUCES RAPID REGRESSION OF ESTABLISHED B-CELL LYMPHOMA", "year": "1994"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:BUYA1_V_uYcC", "citedby": "0"}, {"bib": {"title": "THE ROLE OF ANTIBODY FC AND T-CELL ACTIVATION IN CD3-BASED BISPECIFIC MONOCLONAL-ANTIBODY THERAPY", "year": "1993"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:Y5dfb0dijaUC", "citedby": "0"}, {"bib": {"title": "BISPECIFIC ANTIBODY-INDUCED CYTOLYSIS OF MALIGNANT B-CELLS BY T-CELLS IS ENHANCED BY THE PRESENCE OF CELL-SURFACE IMMUNE-COMPLEXES", "year": "1990"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:MLfJN-KU85MC", "citedby": "0"}, {"bib": {"title": "CpG oligodeoxynucleotides enhance FccRI-mediated cross presentation by dendritic cells"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:bKqednn6t2AC", "citedby": "0"}, {"bib": {"title": "Novel RNA Aptamer-siRNA Chimeras to Target Immunosuppressive T-Regulatory Cells"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:HIFyuExEbWQC", "citedby": "0"}, {"bib": {"title": "Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:sNmaIFBj_lkC", "citedby": "0"}, {"bib": {"title": "Other Classes"}, "source": "citations", "id_citations": "GZWSZq4AAAAJ:PELIpwtuRlgC", "citedby": "0"}]}